期刊
LEUKEMIA & LYMPHOMA
卷 51, 期 8, 页码 1444-1449出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2010.486878
关键词
Multiple myeloma; very elderly; thalidomide; pegylated liposomal doxorubicin
The outcome of patients with multiple myeloma (MM) aged over 75 years remains poor, and the best therapeutic approach has still to be defined. We compared the response, toxicity, and outcome of 34 very elderly patients with MM receiving thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) to those of 34 patients matched for age, International Staging System (ISS), and creatinine who received melphalan, prednisone, thalidomide (MPT). ThaDD resulted in a significantly higher response: >= PR (87.5% vs. 61.5%, p = 0.009) and >= VGPR (55.5% vs. 29.5%; p = 0.03). No statistical differences were detected in terms of median progression-free survival (PFS) and overall survival (OS) between the two treatments. Patients treated with MPT had more neutropenia, neuropathy, and heart toxicity, whereas thromboembolism resulted more frequently in patients receiving ThaDD. Therapy discontinuation occurred in 9% and 14.5% of patients treated with ThaDD and MPT, respectively. ThaDD can be considered a therapeutic option in very elderly patients with MM since it induces a faster and deeper response than that obtained with MPT, having similar safety profile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据